Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: ruxolitinib
Trade Name: Jakafi
Date Designated: 03/26/2010
Orphan Designation: Treatment of polycythemia vera
Orphan Designation Status: Designated/Approved
Incyte Corporation
1801 Augustine Cut-Off
Wilmington, Delaware 19803
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: ruxolitinib
Trade Name: Jakafi
Marketing Approval Date: 12/04/2014
Approved Labeled Indication: Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.
Exclusivity End Date: 12/04/2021 
Exclusivity Protected Indication* :  Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.
*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.
-
-